SAFit2 is primarily utilized in research focused on stress-related disorders and neurodegenerative diseases. It functions as a selective inhibitor of FKBP51, a co-chaperone protein implicated in cellular stress responses, glucocorticoid receptor signaling, and inflammation. Researchers employ SAFit2 to study its potential neuroprotective and antidepressant effects, particularly in conditions like Alzheimer's disease, Parkinson's disease, anxiety, and depression. Additionally, it is investigated for its role in modulating cellular pathways that could lead to the development of novel therapeutic strategies for stress-induced conditions. Its application in preclinical studies, including animal models, helps in understanding the molecular mechanisms underlying these diseases and in identifying potential drug targets.